{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:39:33Z","timestamp":1789699173756,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Accurate prediction of cerebral amyloidosis with easily available indicators is urgently needed for diagnosis and treatment of Alzheimer\u2019s disease (AD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We examined plasma A\u03b242, A\u03b240, T-tau, P-tau181, and NfL, with <jats:italic>APOE<\/jats:italic> genotypes, cognitive test scores and key demographics in a large Chinese cohort (<jats:italic>N<\/jats:italic>\u2009=\u2009609, aged 40 to 84 years) covering full AD spectrum. Data-driven integrated computational models were developed to predict brain \u03b2-amyloid (A\u03b2) pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our computational models accurately predict brain A\u03b2 positivity (area under the ROC curves (AUC)\u2009=\u20090.94). The results are validated in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) cohort. Particularly, the models have the highest prediction power (AUC\u2009=\u20090.97) in mild cognitive impairment (MCI) participants. Three levels of models are designed with different accuracies and complexities. The model which only consists of plasma biomarkers can predict A\u03b2 positivity in amnestic MCI (aMCI) patients with AUC\u2009=\u20090.89. Generally the models perform better in participants without comorbidities or family histories.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The innovative integrated models provide opportunity to assess A\u03b2 pathology in a non-invasive and cost-effective way, which might facilitate AD-drug development, early screening, clinical diagnosis and prognosis evaluation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s43856-023-00295-9","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:11:42Z","timestamp":1683724302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain \u03b2-amyloid pathology"],"prefix":"10.1038","volume":"3","author":[{"given":"Fengfeng","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-3905","authenticated-orcid":false,"given":"Xiao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dake","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"295_CR1","doi-asserted-by":"publisher","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement, https:\/\/doi.org\/10.1002\/alz.12068 (2020).","DOI":"10.1002\/alz.12068"},{"key":"295_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res. Ther. 13, 80 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"295_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in Early Alzheimer\u2019s Disease. N. Engl. J. Med. 384, 1691\u20131704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"295_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","volume":"36","author":"K Blennow","year":"2015","unstructured":"Blennow, K., Mattsson, N., Scholl, M., Hansson, O. & Zetterberg, H. Amyloid biomarkers in Alzheimer\u2019s disease. Trends. Pharmacol. Sci. 36, 297\u2013309 (2015).","journal-title":"Trends. Pharmacol. Sci."},{"key":"295_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"295_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel, H. et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat. Rev. Neurol. 14, 639\u2013652 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"295_CR7","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson, O. et al. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology 88, 930\u2013937 (2017).","journal-title":"Neurology"},{"key":"295_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 76, 791\u2013799 (2019).","journal-title":"JAMA Neurol."},{"key":"295_CR9","first-page":"12","volume":"9","author":"C Udeh-Momoh","year":"2022","unstructured":"Udeh-Momoh, C. et al. Blood Derived Amyloid Biomarkers for Alzheimer\u2019s Disease Prevention. J Prev. Alzheimers Dis. 9, 12\u201321 (2022).","journal-title":"J Prev. Alzheimers Dis."},{"key":"295_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","volume":"16","author":"T West","year":"2021","unstructured":"West, T. et al. A blood-based diagnostic test incorporating plasma Abeta42\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol. Neurodegener. 16, 30 (2021).","journal-title":"Mol. Neurodegener."},{"key":"295_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"295_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"295_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","volume":"15","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer\u2019s disease: Cross-validation study of practical algorithms. Alzheimers Dement. 15, 194\u2013204 (2019).","journal-title":"Alzheimers Dement."},{"key":"295_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze, S. et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma Abeta42\/Abeta40 and p-tau. Alzheimers Dement. 18, 283\u2013293 (2022).","journal-title":"Alzheimers Dement."},{"key":"295_CR15","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/alz.12362","volume":"17","author":"KB Rajan","year":"2021","unstructured":"Rajan, K. B. et al. Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. 17, 1966\u20131975 (2021).","journal-title":"Alzheimers Dement."},{"key":"295_CR16","first-page":"639","volume":"18","author":"M Hassan","year":"2018","unstructured":"Hassan, M. et al. Computational modeling and biomarker studies of550 pharmacological treatment of Alzheimer\u2019s disease. Mol. Med. Rep. 18, 639\u2013655 (2018).","journal-title":"Mol. Med. Rep."},{"key":"295_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-016-0348-2","volume":"10","author":"W Hao","year":"2016","unstructured":"Hao, W. & Friedman, A. Mathematical model on Alzheimer\u2019s disease. BMC Syst. Biol. 10, 108 (2016).","journal-title":"BMC Syst. Biol."},{"key":"295_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neuroimage.2017.02.058","volume":"152","author":"Y Iturria-Medina","year":"2017","unstructured":"Iturria-Medina, Y. et al. Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer\u2019s disease. Neuroimage 152, 60\u201377 (2017).","journal-title":"Neuroimage"},{"key":"295_CR19","first-page":"205","volume":"10435","author":"Y Zhu","year":"2017","unstructured":"Zhu, Y. et al. Personalized Diagnosis for Alzheimer\u2019s Disease. Med. Image Comput. Comput. Assist. Interv. 10435, 205\u2013213 (2017).","journal-title":"Med. Image Comput. Comput. Assist. Interv."},{"key":"295_CR20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/brain\/awy050","volume":"141","author":"NP Oxtoby","year":"2018","unstructured":"Oxtoby, N. P. et al. Data-driven models of dominantly-inherited Alzheimer\u2019s disease progression. Brain 141, 1529\u20131544 (2018).","journal-title":"Brain"},{"key":"295_CR21","doi-asserted-by":"publisher","first-page":"118233","DOI":"10.1016\/j.neuroimage.2021.118233","volume":"238","author":"V Venkatraghavan","year":"2021","unstructured":"Venkatraghavan, V. et al. Progression along data-driven disease timelines is predictive of Alzheimer\u2019s disease in a population-based cohort. Neuroimage 238, 118233 (2021).","journal-title":"Neuroimage"},{"key":"295_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fdata.2020.00024","volume":"3","author":"LL Raket","year":"2020","unstructured":"Raket, L. L. Statistical Disease Progression Modeling in Alzheimer Disease. Front Big Data. 3, 24 (2020).","journal-title":"Front Big Data."},{"key":"295_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.crme.2019.11.009","volume":"347","author":"FJ Mont\u00e1ns","year":"2019","unstructured":"Mont\u00e1ns, F. J., Chinesta, F., G\u00f3mez-Bombarelli, R. & Kutz, J. N. Data-driven modeling and learning in science and engineering. Comptes Rendus M\u00e9canique. 347, 845\u2013855 (2019).","journal-title":"Comptes Rendus M\u00e9canique."},{"key":"295_CR24","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1373\/clinchem.2004.031823","volume":"50","author":"NA Obuchowski","year":"2004","unstructured":"Obuchowski, N. A., Lieber, M. L. & Wians, F. H. Jr. ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin. Chem. 50, 1118\u20131125 (2004).","journal-title":"Clin. Chem."},{"key":"295_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40120-019-00164-5","volume":"8","author":"D Li","year":"2019","unstructured":"Li, D. & Mielke, M. M. An Update on Blood-Based Markers of Alzheimer\u2019s Disease Using the SiMoA Platform. Neurol. Ther. 8, 73\u201382 (2019).","journal-title":"Neurol. Ther."},{"key":"295_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0895-4356(88)90034-0","volume":"41","author":"R Katzman","year":"1988","unstructured":"Katzman, R. et al. A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J. Clin. Epidemiol. 41, 971\u2013978 (1988).","journal-title":"J. Clin. Epidemiol."},{"key":"295_CR27","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2147\/NDT.S174293","volume":"14","author":"L Huang","year":"2018","unstructured":"Huang, L. et al. Chinese version of Montreal Cognitive Assessment Basic for discrimination among different severities of Alzheimer\u2019s disease. Neuropsychiatr. Dis. Treat. 14, 2133\u20132140 (2018).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"295_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/13607863.2021.1881757","volume":"26","author":"FF Pan","year":"2022","unstructured":"Pan, F. F., Wang, Y., Huang, L., Huang, Y. & Guo, Q. H. Validation of the Chinese version of Addenbrooke\u2019s cognitive examination III for detecting mild cognitive impairment. Aging Ment. Health. 26, 384\u2013391 (2022).","journal-title":"Aging Ment. Health."},{"key":"295_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H. Jr., Chance, J. M. & Filos, S. Measurement of functional activities in older adults in the community. J. Gerontol. 37, 323\u2013329 (1982).","journal-title":"J. Gerontol."},{"key":"295_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2174\/1567205012666150530202729","volume":"12","author":"Q Zhao","year":"2015","unstructured":"Zhao, Q. et al. Auditory Verbal Learning Test is Superior to Rey-Osterrieth Complex Figure Memory for Predicting Mild Cognitive Impairment to Alzheimer\u2019s Disease. Curr. Alzheimer Res. 12, 520\u2013526 (2015).","journal-title":"Curr. Alzheimer Res."},{"key":"295_CR31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12877-021-02260-4","volume":"21","author":"S Lee","year":"2021","unstructured":"Lee, S. et al. Serum sodium in relation to various domains of cognitive function in the elderly US population. BMC Geriatr. 21, 328 (2021).","journal-title":"BMC Geriatr."},{"key":"295_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12264-013-1301-7","volume":"29","author":"Q Zhao","year":"2013","unstructured":"Zhao, Q., Guo, Q. & Hong, Z. Clustering and switching during a semantic verbal fluency test contribute to differential diagnosis of cognitive impairment. Neurosci. Bull. 29, 75\u201382 (2013).","journal-title":"Neurosci. Bull."},{"key":"295_CR33","doi-asserted-by":"publisher","first-page":"e57333","DOI":"10.1371\/journal.pone.0057333","volume":"8","author":"Q Zhao","year":"2013","unstructured":"Zhao, Q. et al. The Shape Trail Test: application of a new variant of the Trail making test. PLoS One. 8, e57333 (2013).","journal-title":"PLoS One."},{"key":"295_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"295_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JAD-140276","volume":"42","author":"MW Bondi","year":"2014","unstructured":"Bondi, M. W. et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J. Alzheimers Dis. 42, 275\u2013289 (2014).","journal-title":"J. Alzheimers Dis."},{"key":"295_CR36","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 10, 844\u2013852 (2014).","journal-title":"Alzheimers Dement."},{"key":"295_CR37","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1088\/0031-9155\/61\/15\/5768","volume":"61","author":"G Akamatsu","year":"2016","unstructured":"Akamatsu, G. et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys. Med. Biol. 61, 5768\u20135780 (2016).","journal-title":"Phys. Med. Biol."},{"key":"295_CR38","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1148\/rg.2018180160","volume":"38","author":"TF Lundeen","year":"2018","unstructured":"Lundeen, T. F., Seibyl, J. P., Covington, M. F., Eshghi, N. & Kuo, P. H. Signs and Artifacts in Amyloid PET. Radiographics 38, 2123\u20132133 (2018).","journal-title":"Radiographics"},{"key":"295_CR39","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3233\/JAD-201606","volume":"81","author":"YY Wang","year":"2021","unstructured":"Wang, Y. Y. et al. The Proportion of APOE4 Carriers Among Non-Demented Individuals: A Pooled Analysis of 389,000 Community-Dwellers. J. Alzheimers Dis. 81, 1331\u20131339 (2021).","journal-title":"J. Alzheimers Dis."},{"key":"295_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.dadm.2016.07.002","volume":"4","author":"PS Insel","year":"2016","unstructured":"Insel, P. S. et al. Assessing risk for preclinical beta-amyloid pathology with APOE, cognitive, and demographic information. Alzheimers Dement. (Amst) 4, 76\u201384 (2016).","journal-title":"Alzheimers Dement. (Amst)"},{"key":"295_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29047-4","volume":"13","author":"D Jones","year":"2022","unstructured":"Jones, D. et al. A computational model of neurodegeneration in Alzheimer\u2019s disease. Nat. Commun. 13, 1643 (2022).","journal-title":"Nat. Commun."},{"key":"295_CR42","doi-asserted-by":"publisher","unstructured":"Nabers, A. et al. Amyloid blood biomarker detects Alzheimer\u2019s disease. EMBO Mol. Med. 10, https:\/\/doi.org\/10.15252\/emmm.201708763 (2018).","DOI":"10.15252\/emmm.201708763"},{"key":"295_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13311-016-0481-z","volume":"14","author":"SE Counts","year":"2017","unstructured":"Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E. & Mufson, E. J. Biomarkers for the Early Detection and Progression of Alzheimer\u2019s Disease. Neurotherapeutics 14, 35\u201353 (2017).","journal-title":"Neurotherapeutics"},{"key":"295_CR44","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"295_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000321984","volume":"31","author":"S Crean","year":"2011","unstructured":"Crean, S. et al. Apolipoprotein E epsilon4 prevalence in Alzheimer\u2019s disease patients varies across global populations: a systematic literature review and meta-analysis. Dement Geriatr Cogn. Disord. 31, 20\u201330 (2011).","journal-title":"Dement Geriatr Cogn. Disord."},{"key":"295_CR46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.neubiorev.2021.07.007","volume":"128","author":"Y Qu","year":"2021","unstructured":"Qu, Y. et al. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer\u2019s disease: A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 128, 479\u2013486 (2021).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"295_CR47","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400\u2013418 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"295_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","volume":"14","author":"AL Benedet","year":"2022","unstructured":"Benedet, A. L. et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res. Ther. 14, 26 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"295_CR49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/jnnp-2021-327864","volume":"93","author":"L Cheng","year":"2022","unstructured":"Cheng, L. et al. Plasma Abeta as a biomarker for predicting Abeta-PET status in Alzheimer\u2019s diseasea systematic review with meta-analysis. J. Neurol. Neurosurg. Psychiatry. 93, 513\u2013520 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"295_CR50","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","volume":"48","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur. J. Nucl. Med. Mol. Imaging. 48, 2140\u20132156 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"295_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature 554, 249\u2013254 (2018).","journal-title":"Nature"},{"key":"295_CR52","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen, R. C. et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 126\u2013135 (2018).","journal-title":"Neurology"},{"key":"295_CR53","first-page":"371","volume":"8","author":"AP Porsteinsson","year":"2021","unstructured":"Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N. & Rubino, I. Diagnosis of Early Alzheimer\u2019s Disease: Clinical Practice in 2021. J. Prev. Alzheimers Dis. 8, 371\u2013386 (2021).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"295_CR54","doi-asserted-by":"publisher","unstructured":"Chang, C. H., Lin, C. H. & Lane, H. Y. Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer\u2019s Disease. Int. J. Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms22052761 (2021).","DOI":"10.3390\/ijms22052761"},{"key":"295_CR55","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000499763","volume":"47","author":"M Overton","year":"2019","unstructured":"Overton, M., Pihlsgard, M. & Elmstahl, S. Prevalence and Incidence of Mild Cognitive Impairment across Subtypes, Age, and Sex. Dement Geriatr Cogn Disord 47, 219\u2013232 (2019).","journal-title":"Dement Geriatr Cogn Disord"},{"key":"295_CR56","doi-asserted-by":"publisher","unstructured":"WXDX-DA. WXDX-DA\/AbetaPrediction: Initial Release (v0.1.0). Zenodo. https:\/\/doi.org\/10.5281\/zenodo.7844160 (2023).","DOI":"10.5281\/zenodo.7844160"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00295-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:19:11Z","timestamp":1683728351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00295-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1038\/s43856-023-00295-9","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"23 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}